Successful treatment of angiosarcoma of the scalp with apatinib: a case report.
Successful treatment of angiosarcoma of the scalp with apatinib: a case report.
复制标题
DOI：
10.2147/ott.s110235
复制
发表时间：
2016
影响因子：
4
通讯作者：
Yang P
中科院分区：
文献类型：
--
作者：
Ji G;Hong L;Yang P
血管肉瘤是一种罕见的侵袭性血管恶性肿瘤，预后较差。晚期血管肉瘤没有标准的化疗方案。在此，我们报告一例晚期血管肉瘤患者被阿帕替尼成功治疗，阿帕替尼是一种口服酪氨酸激酶抑制剂，针对血管内皮生长因子受体 2 (VEGFR-2) 的细胞内结构域。据我们所知，这是首例报告阿帕替尼成功用于治疗血管肉瘤的病例。此外，与传统的细胞毒性化疗相比，阿帕替尼的毒性作用更少。定量聚合酶链反应分析显示VEGFR-2 mRNA高表达，表明阿帕替尼通过抑制VEGFR-2酪氨酸激酶活性而产生临床缓解，VEGFR-2在血管肉瘤中发挥着至关重要的作用。阿帕替尼可能是血管肉瘤的另一种选择，特别是对于老年人和体能状态不佳的患者。需要进一步的前瞻性研究来优化阿帕替尼在血管肉瘤患者中的使用，并确定哪些患者将从该药物中受益。
Angiosarcoma is a rare and aggressive vascular malignancy with a poor prognosis. There is no standard chemotherapy regime for advanced angiosarcoma. Here, we report a case of advanced angiosarcoma that was successfully treated with apatinib, an oral tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). To our knowledge, this is the first case to report the successful use of apatinib for angiosarcoma. Furthermore, the administration of apatinib results in fewer toxic effects than traditional cytotoxic chemotherapy. Quantitative polymerase chain reaction analysis revealed high expression of VEGFR-2 mRNA, suggesting that apatinib leads to clinical response by inhibiting VEGFR-2 tyrosine kinase activity and that VEGFR-2 plays a crucial role for angiosarcoma. Apatinib may be an additional option for angiosarcoma especially for the aged and patients with poor performance status. Further prospective studies are required to optimize the use of apatinib in patients with angiosarcoma and to identify which patients will benefit from the agent.